azacitidine and Nausea

azacitidine has been researched along with Nausea in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19907 (35.00)18.7374
1990's2 (10.00)18.2507
2000's1 (5.00)29.6817
2010's7 (35.00)24.3611
2020's3 (15.00)2.80

Authors

AuthorsStudies
Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J1
Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L1
Afanasyev, B; Beach, CL; Beltrami, G; Borin, L; Botelho de Sousa, A; Čermák, J; Döhner, H; Dombret, H; Dong, Q; Frairia, C; Giai, V; Jang, JH; Kizil Çakar, M; Kumar, K; La Torre, I; Montesinos, P; Ofran, Y; Ossenkoppele, GJ; Pocock, C; Porkka, K; Ravandi, F; Roboz, GJ; Rybka, J; Sandhu, I; Sayar, H; Selleslag, D; Skikne, B; Turgut, M; Wei, AH1
Ahuja, N; Anders, NM; Azad, N; Downs, M; Durham, JN; Gaillard, SL; Reiss, KA; Rudek, MA; Sartorius-Mergenthaler, S; Sharma, A; Zahurak, M1
Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E1
Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X1
Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L1
Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D1
Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C1
Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B1
Breed, C; Latsko, JM; Shadduck, RK; Stone, R1
Creagan, ET; Hartmann, LC; Loprinzi, CL; Schaid, DJ1
Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA1
Cohen, FB; Custodio, MC; Decter, JA; Lippman, AJ1
Muggia, FM; Slavik, M; Von Hoff, DD1
Keller, JW; Miller, DS; Vogler, WR1
Arkun, SN; Bartolucci, AA; Vélez-Garcia, E; Vogler, WR1
Baehner, RL; Berkow, RL; Weetman, RM; Weisman, SJ1
Hahn, RG; Moertel, CG; Reitemeier, RJ; Schutt, AJ1
Finklestein, JZ; Karon, M; Leimbrock, S; Nesbit, ME; Sieger, L; Swaney, JJ1

Reviews

2 review(s) available for azacitidine and Nausea

ArticleYear
New antineoplastic drugs and their proper use.
    The Medical clinics of North America, 1976, Volume: 60, Issue:5

    Topics: Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Bone Marrow Diseases; Dacarbazine; Doxorubicin; Humans; Liver; Nausea; Neoplasms; Nitrosourea Compounds; Pancreatitis; Pulmonary Fibrosis; Vomiting

1976
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
    Annals of internal medicine, 1976, Volume: 85, Issue:2

    Topics: Animals; Azacitidine; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; Europe; Female; Humans; Kinetics; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukopenia; Liver; Nausea; Neoplasms, Experimental; Neuromuscular Diseases; RNA, Messenger; United States; Vomiting

1976

Trials

14 trial(s) available for azacitidine and Nausea

ArticleYear
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
    Leukemia, 2023, Volume: 37, Issue:10

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea

2023
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
    The New England journal of medicine, 2020, 12-24, Volume: 383, Issue:26

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Survival Analysis

2020
A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
    Cancer, 2019, 08-15, Volume: 125, Issue:16

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Depsipeptides; DNA Modification Methylases; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Long Interspersed Nucleotide Elements; Male; Maximum Tolerated Dose; Methyltransferases; Middle Aged; Nausea; Neoplasms

2019
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
    Leukemia research, 2014, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat

2014
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Cancer, 2015, Jul-15, Volume: 121, Issue:14

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome

2015
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
    Blood, 2011, Aug-11, Volume: 118, Issue:6

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult

2011
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome

2012
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome

2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
    Haematologica, 2013, Volume: 98, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting

2013
A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Chest Pain; Female; Humans; Immunologic Factors; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nausea; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Vomiting

1993
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:12 Pt 1

    Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia

1997
Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Cancer treatment reports, 1977, Volume: 61, Issue:9

    Topics: Azacitidine; Clinical Trials as Topic; Drug Evaluation; Granulocytes; Humans; Infusions, Parenteral; Leukopenia; Nausea; Neoplasm Metastasis

1977
Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Azacitidine; Blood Cell Count; Blood Platelets; Clinical Trials as Topic; Cytidine; Female; Gastrointestinal Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Nausea; Triazines; Vomiting

1972
5-Azacytidine: a new active agent for the treatment of acute leukemia.
    Blood, 1973, Volume: 42, Issue:3

    Topics: Adolescent; Azacitidine; Bone Marrow Examination; Child; Child, Preschool; Chlorpromazine; Clinical Trials as Topic; Cytidine; Digestive System; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Nausea; Remission, Spontaneous; Triazines

1973

Other Studies

4 other study(ies) available for azacitidine and Nausea

ArticleYear
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    British journal of haematology, 2020, Volume: 189, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting

2020
MDS: practical treatment approaches for physicians and nurses.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:2

    Topics: Azacitidine; Bone Marrow Transplantation; Decision Trees; DNA Methylation; Drug Administration Schedule; Hematopoietic Cell Growth Factors; Humans; Injections, Subcutaneous; Medical Oncology; Myelodysplastic Syndromes; Nausea; Oncology Nursing

2005
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.
    Blood, 1976, Volume: 48, Issue:3

    Topics: Agranulocytosis; Azacitidine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nausea; Neoplasm Metastasis; Vomiting

1976
5-Azacytidine: acute central nervous system toxicity.
    The American journal of pediatric hematology/oncology, 1985,Spring, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Central Nervous System; Child; Humans; Leukemia, Monocytic, Acute; Male; Nausea; Vomiting

1985